Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass' pipeline of novel product candidates targets critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance.

Compass plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company's lead product candidate, CTX-009, is a bispecific antibody that simultaneously blocks Delta-like ligand four (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways. CTX-009 has demonstrated robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. In April 2024, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract cancer (BTC). Compass is currently evaluating this combination in a randomized Phase 2/3 study for BTC, with top line data expected by the end of 2024.

Another key candidate in Compass' pipeline is CTX-471, a fully human monoclonal antibody that binds and activates the co-stimulatory receptor CD137 (4-1BB). CTX-471 has demonstrated potent monotherapy activity against multiple syngeneic tumor models and is being evaluated in a Phase 1 billion clinical trial for solid tumors.